COSCIENS Biopharma Inc
CSCI3.880USD
+0.060+1.57%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
12.21MCap. mercado
PérdidaP/E TTM
Más Datos de COSCIENS Biopharma Inc Compañía
COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
Información de la empresa
Símbolo de cotizaciónCSCI
Nombre de la empresaCOSCIENS Biopharma Inc
Fecha de salida a bolsaDec 19, 1995
Director ejecutivoMs. Anna Biehn
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 19
DirecciónC/O Norton Rose Fulbright Canada Llp
CiudadTORONTO
Bolsa de valoresThe Toronto Stock Exchange
PaísCanada
Código postalM5K 1E7
Teléfono18439003201
Sitio Webhttps://www.cosciensbio.com/
Símbolo de cotizaciónCSCI
Fecha de salida a bolsaDec 19, 1995
Director ejecutivoMs. Anna Biehn
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Gilles R. Gagnon
Mr. Gilles R. Gagnon
Director
Director
41.96K
--
Dr. Ulrich Kosciessa
Dr. Ulrich Kosciessa
Director
Director
1.85K
--
Ms. Nicola Ammer
Ms. Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
--
--
Mr. Pierre Labbe, CPA
Mr. Pierre Labbe, CPA
Director
Director
--
--
Dr. Matthias Gerlach
Dr. Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
--
--
Mr. Giuliano La Fratta
Mr. Giuliano La Fratta
Chief Financial Officer, Senior Vice President, Director
Chief Financial Officer, Senior Vice President, Director
--
--
Ms. Genevieve Foster
Ms. Genevieve Foster
Director
Director
--
--
Dr. William W. Li, M.D.
Dr. William W. Li, M.D.
Director
Director
--
--
Mr. Michel Regnier
Mr. Michel Regnier
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Ronald W. (Ronnie) Miller
Mr. Ronald W. (Ronnie) Miller
Chairman of the Board
Chairman of the Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Gilles R. Gagnon
Mr. Gilles R. Gagnon
Director
Director
41.96K
--
Dr. Ulrich Kosciessa
Dr. Ulrich Kosciessa
Director
Director
1.85K
--
Ms. Nicola Ammer
Ms. Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
--
--
Mr. Pierre Labbe, CPA
Mr. Pierre Labbe, CPA
Director
Director
--
--
Dr. Matthias Gerlach
Dr. Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
--
--
Mr. Giuliano La Fratta
Mr. Giuliano La Fratta
Chief Financial Officer, Senior Vice President, Director
Chief Financial Officer, Senior Vice President, Director
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de abr
Divisa: USDActualizado: dom., 6 de abr
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
Switzerland
4.32M
95.98%
Ireland
122.00K
2.71%
Other
48.00K
1.07%
Denmark
11.00K
0.24%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 1 de ago
Actualizado: vie., 1 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Goodwood Inc.
8.18%
Gagnon (Gilles R)
1.33%
Susquehanna International Group, LLP
0.38%
RBC Dominion Securities, Inc.
0.12%
TD Waterhouse Canada, Inc.
0.12%
Other
89.87%
Accionistas
Accionistas
Proporción
Goodwood Inc.
8.18%
Gagnon (Gilles R)
1.33%
Susquehanna International Group, LLP
0.38%
RBC Dominion Securities, Inc.
0.12%
TD Waterhouse Canada, Inc.
0.12%
Other
89.87%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
8.19%
Individual Investor
1.49%
Investment Advisor
0.70%
Research Firm
0.11%
Bank and Trust
0.04%
Other
89.47%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
37
331.27K
10.53%
-6.89K
2025Q1
40
333.44K
10.61%
+29.17K
2024Q4
39
327.35K
8.67%
+13.77K
2024Q3
37
287.99K
7.73%
+16.16K
2024Q2
43
256.95K
8.09%
+189.65K
2024Q1
39
61.15K
4.98%
+40.02K
2023Q4
42
13.03K
1.07%
-9.47K
2023Q3
49
18.14K
1.49%
-6.74K
2023Q2
52
14.44K
1.19%
-13.85K
2023Q1
54
14.56K
1.20%
-15.46K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Goodwood Inc.
257.26K
8.18%
--
--
Jun 03, 2025
Gagnon (Gilles R)
41.96K
1.33%
--
--
Mar 26, 2025
Susquehanna International Group, LLP
11.91K
0.38%
+11.91K
--
Mar 31, 2025
RBC Dominion Securities, Inc.
3.87K
0.12%
-69.00
-1.75%
Mar 31, 2025
TD Waterhouse Canada, Inc.
3.72K
0.12%
--
--
Mar 31, 2025
Desjardins Securities Inc.
2.81K
0.09%
-1.06K
-27.39%
Mar 31, 2025
Li (William W. M.D.)
2.40K
0.08%
--
--
Mar 26, 2025
UBS Financial Services, Inc.
2.34K
0.07%
+1.65K
+240.67%
Mar 31, 2025
Kosciessa (Ulrich)
1.85K
0.06%
--
--
Jun 03, 2025
National Bank of Canada
1.12K
0.04%
-4.80K
-81.05%
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
May 01, 2024
Merger
4<1
May 01, 2024
Merger
4<1
May 01, 2024
Merger
4<1
May 01, 2024
Merger
4<1
Jul 19, 2022
Merger
25<1
Jul 19, 2022
Merger
25<1
Fecha
Tipo
Relación
May 01, 2024
Merger
4<1
May 01, 2024
Merger
4<1
May 01, 2024
Merger
4<1
May 01, 2024
Merger
4<1
Jul 19, 2022
Merger
25<1
Jul 19, 2022
Merger
25<1
Jul 19, 2022
Merger
25<1
Jul 19, 2022
Merger
25<1
